Research & Publications

Translational research has always been the linchpin of Lifedoc’s clinical framework, further enabling us to provide healthcare that is quality-oriented and data-driven. Over the last 15 years, research has remained an integral part of our efforts to maximize the applicability of health data. With active participation in industry-sponsored and investigator-initiated research, we aim to to inform emerging treatments and continually refine our clinical model for the ultimate benefit of the patient. This focus allows us to continually develop data to support our evidence-based approach, ensuring that our patients receive the most effective healthcare and clinical interventions. Ultimately, this allows us to fulfill our mission of establishing Lifedoc as a reference model for researchers and practitioners studying the development and prevention of cardiometabolic conditions.

Take a look at our past and ongoing trials, research partnerships as well as some of our published/presented studies below.

Interested in working with our research site? Contact us.

Quality care for all. A kid playing doctor.

Research Partnerships

Novo Nordisk

Industry-sponsored Clinical Trials

Ongoing Trials

– Boehringer-Ingleheim – Safety and Efficacy of SGLT-2 and DPP-4 in Type 2 Diabetes, Children 10 – 17 years of age.

Past Trials

– Janssen – Safety and Efficacy of SGLT-2  in Type 2 Diabetes, Adults – Recognized as Highest Recruiting/Retaining Site in the US

– Novo Nordisk – Safety and Efficacy of Liraglutide in Overweight and Obesity, Children and Adolescents 10-17 years of age – Recruited First and Second Patient Globally

–  Novo Nordisk – Safety and Efficacy of Liraglutide and Metformin in Type 2 Diabetes, Children and Adolescents 10-17 years of age – Recognized as Highest Recruiting Site in the US

Notable Publications

Published: The Lancet Global Health
Authors: Safia S Jiwani 1 , Rodrigo M Carrillo-Larco 2 , Akram Hernández-Vásquez 3 , Tonatiuh Barrientos-Gutiérrez 4 , Ana Basto-Abreu 4 , Laura Gutierrez 5 , Vilma Irazola 5 , Ramfis Nieto-Martínez 6 , Bruno P Nunes 7 , Diana C Parra 8 , J Jaime Miranda 9
Background: The burden of obesity differs by socioeconomic status. We aimed to characterize the prevalence of obesity among adult men and women in Latin America and the Caribbean by socioeconomic measures and the shifting obesity burden over time.
Published: Primary Care Diabetes
Authors: Ramfis Nieto-Martínez 1 , Juan P González-Rivas 2 , Eunice Ugel 3 , Maria Ines Marulanda 4 , Maritza Durán 5 , Jeffrey I Mechanick 6 , Pablo Aschner 7
To evaluate the performance of the Latin American Finnish Diabetes Risk Score (LA-FINDRISC) compared with the original O-FINDRISC in general population. To establish the best cut-off to detect unknown type 2 diabetes (uT2D) and prediabetes.
Published: Diabetes Technology & Therapeutics
Authors: Mary E Larkin 1 , David M Nathan 1 , Ionut Bebu 2 , Heidi Krause-Steinrauf 2 , William H Herman 3 , John M Higgins 4 5 , Margaret Tiktin 6 , Robert M Cohen 7 , Claire Lund 2 , Richard M Bergenstal 8 , Mary L Johnson 8 , Valerie Arends 9 , GRADE Research Group
The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) study has enrolled a racially and ethnically diverse population with type 2 diabetes, performed extensive phenotyping, and randomly assigned the participants to one of four second-line diabetes medications.
Published: Diabetes Care
Authors: Deborah J Wexler 1 , Heidi Krause-Steinrauf 2 , Jill P Crandall 3 , Hermes J Florez 4 , Sophia H Hox 5 , Alexander Kuhn 6 , Ajay Sood 7 , Chantal Underkofler 8 , Vanita R Aroda 6 , GRADE Research Group
GRADE (Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study) is a 36-center unmasked, parallel treatment group, randomized controlled trial evaluating four diabetes medications added to metformin in people with type 2 diabetes (T2DM).
Published: Primary Care Diabetes
Authors: Juan Pablo González-Rivas 1 , William Polonsky 2 , María María Infante-García 3 , Maritza Duran 4 , Eunice Ugel 5 , María Ines Marulanda 6 , Jeffrey I Mechanick 7 , Ramfis Nieto-Martínez 8
Evidence suggests that depression is more common in patients with diabetes than in the general population. However, contradictory results expose controversy in this association.

Contact Us